Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
AURA · Why this verdict
Why Aura Biosciences (AURA) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.4/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Aura Biosciences is a cash-burning, single-pipeline biotech trading at $6.30 with large analyst-implied upside, but weak quality, high leverage and negative momentum make it a speculative binary bet.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Value rests on one pipeline asset (bel-sar), and a high-leverage reading (D/E 5.2) plus a 184% implied volatility reading mark binary outcome risk. Bear case | Clinical milestones for bel-sar are met without a delay or safety issue in the next 12 months. | →Stable |
| CounterWith one asset, any trial failure or regulatory delay is existential, and the C-suite change flagged in a recent filing adds execution risk. | ||
Short interest of 10% and below-average business quality make the stock vulnerable to further downside if financing or trial news disappoints. Key risks | Short interest declines from 10% as trial progress reduces uncertainty. | →Stable |
| CounterShorts may simply be expressing the correct view on cash burn and leverage, so a falling short count is not guaranteed to follow good news. | ||
Analysts see substantial upside: the analyst target of $14.44 implies 129.2% upside from the $6.30 price, against 9.1% downside to the stop. Targets | Price moves meaningfully toward the analyst target as pipeline milestones are reached over 12 months. | →Stable |
| CounterTargets for pre-revenue biotechs hinge on one trial outcome, and coverage is light, so the target can be cut sharply on a single setback. | ||
The business is cash-burning with negative free cash flow, no competitive moat and an overall quality score of 1.6, below the 4.0 floor. Quality breakdown | Cash burn stays funded and quality metrics improve as the pipeline matures. | →Stable |
| CounterA quality score of 1.6 means the company depends on outside financing; dilution or a funding gap could destroy equity value before any approval. | ||
Price is below the 200-day average, but that average is still rising 0.8% per 30 days, so the weakness looks like a pullback in an uptrend rather than a confirmed breakdown. Momentum breakdown | Price reclaims the 200-day average and on-balance volume stops falling. | ↑Improving |
| CounterFalling on-balance volume shows distribution, and a momentum score of 3.3 suggests sellers still control the tape. | ||
Value rests on one pipeline asset (bel-sar), and a high-leverage reading (D/E 5.2) plus a 184% implied volatility reading mark binary outcome risk.
→StableBear case
- Expectation
- Clinical milestones for bel-sar are met without a delay or safety issue in the next 12 months.
CounterWith one asset, any trial failure or regulatory delay is existential, and the C-suite change flagged in a recent filing adds execution risk.
Short interest of 10% and below-average business quality make the stock vulnerable to further downside if financing or trial news disappoints.
→StableKey risks
- Expectation
- Short interest declines from 10% as trial progress reduces uncertainty.
CounterShorts may simply be expressing the correct view on cash burn and leverage, so a falling short count is not guaranteed to follow good news.
Analysts see substantial upside: the analyst target of $14.44 implies 129.2% upside from the $6.30 price, against 9.1% downside to the stop.
→StableTargets
- Expectation
- Price moves meaningfully toward the analyst target as pipeline milestones are reached over 12 months.
CounterTargets for pre-revenue biotechs hinge on one trial outcome, and coverage is light, so the target can be cut sharply on a single setback.
The business is cash-burning with negative free cash flow, no competitive moat and an overall quality score of 1.6, below the 4.0 floor.
→StableQuality breakdown
- Expectation
- Cash burn stays funded and quality metrics improve as the pipeline matures.
CounterA quality score of 1.6 means the company depends on outside financing; dilution or a funding gap could destroy equity value before any approval.
Price is below the 200-day average, but that average is still rising 0.8% per 30 days, so the weakness looks like a pullback in an uptrend rather than a confirmed breakdown.
↑ImprovingMomentum breakdown
- Expectation
- Price reclaims the 200-day average and on-balance volume stops falling.
CounterFalling on-balance volume shows distribution, and a momentum score of 3.3 suggests sellers still control the tape.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 6.7 |
| OBV | 10.0 |
| MA position | 5.2 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA but MA still rising (+1.0%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 159%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 2.2 |
| growth rank | 5.0 |
Technical
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.7 |
| support resistance | 4.4 |
| 52w position | 3.5 |
Risk (lower is worse)
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.7 |
| days to cover | 0.0 |
| volatility | 2.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 10.0 |
| debt equity | 9.8 |
- ▸High IV: 271%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 5.6 |
| earnings timing | 5.0 |
| surprise avg | 2.9 |
- ▸Earnings in 13 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- MOMENTUM:5.3>=4.5
- ASYMMETRY:14.8>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (3)
- MOMENTUM:5.3<5.5 (soft — BUY_NOW allowed but watch)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
- EARNINGS_PROXIMITY:13d<=14d (soft)
Reward-to-Risk
14.84
Upside
+125.0%
Downside
8.4%
Sizing output
AVOID
SetupRange Bound — RSI 47 mid-range, Bollinger mid-band
EdgeInst Constrain — Small cap ($0.7B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Value at 9.0 and asymmetric R:R of 14.84.
The strongest dimensions are Value at 9.0, Insider at 7.3, and Sentiment at 6.6; the weakest are Quality at 1.6, Technical at 3.9, and Peer rank at 4.4. The V9 engine cleared all gates with 3 warnings, producing an asymmetric reward-to-risk of 14.84 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Analyst Implied Upside
Trip ifAnalyst target falls below $9 from the current $14.44.
- P2Cash Burn No Moat
Trip ifQuality score stays below 4.0 from the current 1.6 for 2 consecutive quarters.
- P3Single Pipeline Concentration
Trip ifDebt-to-equity exceeds 6.0 from the current 5.2.
- P4Pullback In Uptrend
Trip ifPrice falls below the $5.86 stop level from the current $6.30.
- P5Short Interest And Dilution Risk
Trip ifShort interest rises above 15% from the current 10%.